Formosa Pharmaceuticals Pipeline
APP13007 Phase 2 Summary
Response rate strongly suggests APP13007 outperforms competitors in reducing inflammation and pain for critical Phase 3 endpoints
* Graphs are a comparison of published clinical data; These data are not from a head-to-head clinical study.
APP13007 is available for regional or global partnering/licensing.